https://doi.org/10.4081/reumatismo.2026.1947
Acute lung injury timely associated with the administration of tocilizumab
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 29 January 2026
Dear editor,
The interleukin-6 receptor inhibitor tocilizumab has been successfully used to treat various autoimmune diseases and has an acceptable, well-established safety profile...
Downloads
Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C, Dougados M, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 2022; 8: e002359. DOI: https://doi.org/10.1136/rmdopen-2022-002359
Sugihara K, Wakiya R, Shimada H, Kato M, Kameda T, Nakashima S, et al. Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report. Allergy Asthma Clin Immunol 2021; 17: 90. DOI: https://doi.org/10.1186/s13223-021-00594-7
Sangüesa Gómez C, Flores Robles BJ, Jara Chinarro B, Espinosa Malpartida M, Barbadillo Mateos C. Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra. Reumatol Clin 2016; 12: 345-7. DOI: https://doi.org/10.1016/j.reumae.2015.08.005
Liu Y, Chen L. Impact of interleukin 6 levels on acute lung injury risk and disease severity in critically ill sepsis patients. World J Clin Cases 2024; 12: 5374-81. DOI: https://doi.org/10.12998/wjcc.v12.i23.5374
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
